Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
Luo
Ji
J
Howard Hughes Medical Institute, USA.
Manning
Brendan D
BD
Cantley
Lewis C
LC
D000818:Animals; D002453:Cell Cycle; D002455:Cell Division; D002470:Cell Survival; D006801:Humans; D051379:Mice; D023421:Models, Animal; D009369:Neoplasms / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000503:physiopathology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D010766:Phosphorylation; D025941:Protein Interaction Mapping; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D015398:Signal Transduction
D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; C494918:AKT1 protein, human